Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin action in patients at increased vascular risk: modulation by antihypertensive and endocrine replacement therapy
2006-001562-16Phase 4Completed
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Sep 2006
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bendroflumethiazide, amlodipine and dehydroepiandrosterone in essential hypertension and insulin resistance (IR) (5 arms), sponsored by Belfast Health and Social Care Trust. Primary endpoint: Insulin resistance measured by hyperinsulinaemic euglycaemic glucose clamps. Started Sep 2006; status: completed.
02
Drugs
bendroflumethiazideamlodipinedehydroepiandrosterone
03
Conditions
essential hypertensioninsulin resistance (IR)
Beyond the preview
Go deeper on 2006-001562-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001562-16.